 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Dare Bioscience files to sell 15M shares of common stock for holders

Dare Bioscience files $200M mixed securities shelf

Dare Bioscience reports FY23 EPS (35c), consensus (38)

Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to...

Dar  Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of...

DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at...

Dar  Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Dare Bioscience to present additional data from Phase 2b RESPOND study

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual...

Dare  Bioscience to Present at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting

Dare Bioscience announces completion of end-of-Phase 2 meeting with U.S. FDA

There are no FDA-approved treatments for female sexual arousal disorderSAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, and...

Dare  Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Volume (M)	555,803.00
52-Wk High	$1.10
52-Wk Low	$0.27

DARE Dare Bioscience Inc

About

Feed

News

Earnings

Fundamentals